Diabetes Mellitus
Özet
Diyabet; insülin eksikliği veya etkisindeki defektler nedeniyle karbonhidrat, yağ ve protein metabolizmasının bozulduğu kronik bir hastalıktır. Tanıda açlık plazma glukozu (APG ≥126 mg/dl), 75 gramlık OGTT 2. saat glukozu (≥200 mg/dl), rastgele kan glukozu (≥200 mg/dl ve semptom varlığı) ve HbA1c (≥%6.5) kriterleri kullanılır. Gestasyonel diyabet taraması gebeliğin 24-28. haftalarında tek veya iki aşamalı testlerle gerçekleştirilir. Diyabet etiyolojik olarak Tip 1, Tip 2, Gestasyonel ve genetik, ekzokrin veya ilaç kaynaklı diğer spesifik tipler şeklinde sınıflandırılır. Tip 1 diyabette mutlak insülin eksikliği varken; Tip 2 diyabette insülin direnci, sekresyon azalması ve inkretin yetersizliği rol oynar. Genel glisemik kontrol hedefleri APG 80-130 mg/dl, postprandiyal glukoz <160 mg/dl ve HbA1c ≤%7 olmakla birlikte bireyselleştirilmelidir. Tedavide tıbbi beslenme, haftada en az 150 dakika orta şiddette aerobik egzersiz ile direnç egzersizleri yer alır. İlaç tedavisinde biguanidler (metformin), sekretogoglar, TZD, alfa glukozidaz inhibitörleri, inkretin bazlı ilaçlar (GLP-1A, DPP4-İ), SGLT2 inhibitörleri ve insülin rejimleri kullanılır. Akut komplikasyonlar ketoasidoz, hiperozmolar durum, laktik asidoz ve hipoglisemidir; kronik komplikasyonlar ise kardiyovasküler makrovasküler sorunlar ile retinopati, nefropati ve nöropati gibi mikrovasküler hasarlardır.
Referanslar
Türkiye Endokrinoloji ve Metabolizma Derneği, Diabetes Mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu, 2020
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
The International Expert Committee. International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
Vandorsten JP, Dodson WC, Espeland MA, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements 2013;29:1–31.
WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. WHO, Geneva, 1999. WHO/NCD/NCS/99.2.
DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl .2):127-38.
World Health Organization: Classification of Diabetes Mellitus. Geneva; 2019.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.
Cosson E, Benchimol M, Carbillon L, et al. Universal rather than selective screening for gestational diabetes mellitus may improve fetal outcomes. Diabetes Metab 2006;32:140-6.
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: Abbreviated report of a WHO Consultation. World Health Organization 2011, WHO/NMH/CHP/CPM/11.1.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl1):66-76.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358:2560-72.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-86.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
American Diabetes Association. Facilitating behavior change and well-being to Improve health outcomes: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1):S48–S65.
American Diabetes Association. Lifestyle management: Standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl.1):S46-S60.4.
American Diabetes Association. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2019. Diabetes Care 2019;42 (Suppl. 1):S81-S89.
Diabetes UK Nutrition Working Group. Evidence-based nutrition guidelines for the prevention and management of diabetes March 2018.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2018 executive summary. Endocr Pract 2018;24:91-120.
The Look Ahead Research Group, Wing RR. Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: Four year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566–75.
Castaneda C, Layne JE, Munoz-Orians L, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002;25:2335-41.
Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2065-2079
Riddell MC, Gallen IW, Smart CE et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017 May;5(5):377-390.
Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic exercise training, resistance exercise, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007;147:357-69.
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl. 1):S73–S85.
Diabetes Canada Clinical Practice Guidelines Expert Committee; Lipscombe L, Booth G, Butalia S, et al. 2018 Clinical Practice Guidelines: Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018;42:S88–S103.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm– 2018 executive summary. Endocr Pract 2018;24:91-120.
Marso SP, Bain SC, ConsoliA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44.
Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375:311–22.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med 2019;380:347-57.
Zinman B, Wanner C, Lachin JM, et al.; EM-PA-REG OUTCOME Investigators. Empaglifloz-in, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
Monnier L, Owens DR, Bolli GB. The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation. Diabetes & Metabolism 2016;42:77-79.
Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-44.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-86.
Slama G,Traynard PY, Desplanque N, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med 1990;150:589-93.
Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.
Gaede P,Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2017;2(14). pii: 93751.
The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic ne-phropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-20.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disea-se. Kidney Int Suppl. 2013;3:1–150
American Diabetes Association. Microvascular complications and foot care: Standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl. 1):S124–S138.
Iqbal Z, Azmi S, Yadav R, et al. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clin Ther.2018;40(6):828-49
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.